Stamford Pharmaceuticals Inc., a clinical-stage biotechnology company developing science-driven immune therapies, focused on cutaneous and visceral cancers, today announced that Dr John Silke will be joining Stamford, as a scientific advisor. Professor Silke joins Professors Edward Mocarski and Siddharth Balachandran, advising Stamford in the areas of programmed cell death, encompassing apoptotic and necroptotic cell death, and are members of the Company’s scientific advisory board. Professor Silke is currently a Theme Leader at the Walter and Eliza Hall Institute in Melbourne, Australia, and a Professor at the University of Melbourne. He has made significant contributions on the roles of Ubiquitin E3 ligases and RIP Kinases in regulating signalling and effecting inflammation, apoptotic and necroptotic cell death.

“We are delighted to have Professor Silke join our scientific advisory board, accompanying Professors Mocarski and Balachandran. All three eminent scientists are leaders at the vanguard of immunogenic cell death in cancer and virology. We feel that this deep understanding in this important area, can be leveraged by Stamford to develop innovative and novel treatments addressing multiple cancers.” Said Dr Clement Leong. PhD, CEO of Stamford Pharmaceuticals.

Press Release: Stamford Expands its Scientific Advisory Team.